- Markets
Find out what influences market movements by browsing through our tailor made product pages.
- Trading Platforms
Maximise your investment opportunities
Trading Platforms
In order to ensure our customers have the best trading experience. We are proud to introduce our suite of trading platforms.
- Accounts
All accounts can be opened using one application form.
OPEN A LIVE ACCOUNT
The application process is simple and straightforward. You can complete the online application form and be trading in minutes.
- Academy
Here you will find all the details regarding One Financial Markets educational offering
TRADING ACADEMY
Working through each of our six online modules, detailed below, you can develop your trading confidence
- Newsroom
The latest news in the Financial Markets from across the globe.
LATEST NEWS
Make sure you don't miss out on what's going on in the world around you, keep up to date with our market commentary and daily market update videos.
- Contact Us
4 big analyst cuts: Fox stock slips on Wells Fargo downgrade
Investing.com -- Here is your Pro Recap of the biggest analyst cuts you may have missed since yesterday: downgrades for Fox, ImmunityBio, Northrop Grumman, and Diageo.
InvestingPro subscribers got these headlines in real-time. Start your 7-day free trial.
Fox downgraded to Equal Weight after Q3 beat
Wells Fargo downgraded Fox (NASDAQ:FOXA) to Equal Weight from Overweight and cut its price target to $34.00 from $44.00, as reported in real-time on InvestingPro. Shares fell more than 2% pre-market today.
The company reported its Q3 earnings on Tuesday, with EPS and revenues coming in better than the consensus estimates. Total revenues benefitted from advertising revenues rising 43%, primarily due to the impact of the Super Bowl, a higher volume of NFL games, and continued growth at Tubi.
ImmunityBio downgraded to Neutral, shares plunge on FDA’s decision
Piper Sandler downgraded ImmunityBio (NASDAQ:IBRX) to Neutral from Overweight and cut its price target to $4.00 from $10.00.
Shares plummeted more than 55% yesterday after the company announced that it has received a complete response letter from the U.S. Food and Drug Administration (FDA) regarding its Biologics License Application (BLA) for its product candidate, Anktiva (N-803). The letter indicated that the FDA has determined that it cannot approve the BLA in its present form.
2 more downgrades
Barclays downgraded Northrop Grumman (NYSE:NOC) to Equalweight from Overweight and cut its price target to $450.00 from $580.00 to reflect a lower forecast for FCF during the ramp period for B-21/GBSD over the next several years.
According to the firm, Northrop's margins are likely to deteriorate more than expected, diluting a significant portion of growth that is seen on the outlook for B-21/GBSD.
Jefferies downgraded Diageo (NYSE:DEO) to Hold from Buy and cut its price target to $190.00 from $200.00. Shares are down more than 1% pre-market today.
In fast-moving markets, every second counts - and InvestingPro subscribers are always one step ahead with lightning-fast updates.
Start your free 7-day trial now.
Begin trading today! Create an account by completing our form
Privacy Notice
At One Financial Markets we are committed to safeguarding your privacy.
Please see our Privacy Policy for details about what information is collected from you and why it is collected. We do not sell your information or use it other than as described in the Policy.
Please note that it is in our legitimate business interest to send you certain marketing emails from time to time. However, if you would prefer not to receive these you can opt-out by ticking the box below.
Alternatively, you can use the unsubscribe link at the bottom of the Demo account confirmation email or any subsequent emails we send.
By completing the form and downloading the platform you agree with the use of your personal information as detailed in the Policy.